Table 3.
Analysis of basic characteristics between healthy and IBD patients in RNA-seq cohort
| RNA-seq Cohort | Total (n = 73) | Healthy (n = 19) | IBD (n = 54) | P |
|---|---|---|---|---|
| Sex, n(%) | 0.492 | |||
| Female | 26 (35.62) | 8 (42.11) | 18 (33.33) | |
| Male | 47 (64.38) | 11 (57.89) | 36 (66.67) | |
| Age, M (Q1, Q3) | 38.00 (30.00, 51.00) | 41.00 (33.50, 48.00) | 33.50 (28.25, 51.50) | 0.333 |
| BMI, M (Q1, Q3) | 22.14 (20.19, 25.24) | 22.70 (20.59, 24.14) | 22.08 (20.19, 25.53) | 1.000 |
| Albumin(g/L), Mean ± SD | 37.86 ± 5.03 | 38.51 ± 5.16 | 36.02 ± 4.26 | 0.064 |
| Cholesterol (mmol/L), M (Q1, Q3) | 4.00 (3.20, 4.60) | 4.90 (4.45, 5.60) | 3.60 (3.10, 4.20) | < .001* |
| White Blood Cells (× 103/μL), M (Q1, Q3) | 6.73 (4.97, 8.90) | 6.01 (4.92, 8.36) | 6.95 (5.09, 9.38) | 0.285 |
| Erythrocyte Sedimentation Rate(mm/h), M (Q1, Q3) | 4.36 (1.64, 24.69) | 3.04 (1.34, 5.42) | 44.99 (26.66, 50.62) | < .001* |
| CRP(mg/L), M (Q1, Q3) | 2.69 (1.27, 7.89) | 1.76 (1.08, 3.24) | 12.58 (9.70, 15.96) | < .001* |
| Fecal Calprotectin(µg/g), M (Q1, Q3) | 89.28 (46.94, 168.82) | 63.25 (36.29, 107.26) | 255.36 (203.04, 342.90) | < .001* |
SD: standard deviation, M: Median, Q1: 1st Quartile, Q3: 3st Quartile